Table 2 Univariate and multivariate analysis for freedom from locoregional recurrence (FFLRR) and overall survival (OS)
Freedom from locoregional recurrence | Overall Survival | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Univariate | Multivariate | Univariate | Multivariate | |||||||||
Factor | Number | 5 yr FFLRR (%) | p-value | HR | (95 % CI) | p-value | 5 yr OS (%) | p-value | HR | (95 % CI) | p-value | |
Age | <50 | 92 | 93.9 | 0.35 | 83.7 | 0.02 | 1.90 | (0.97-3.7) | 0.06 | |||
> = 50 | 80 | 84.9 | 75 | |||||||||
Combined c stage | II | 111 | 94.5 | 0.00 | 5.51 | (1.35-22.5) | 0.02 | 88.8 | 0.01 | 1.25 | (0.58-2.7) | 0.56 |
III | 61 | 81 | 62.7 | |||||||||
cN stage | o | 69 | 93.6 | 0.21 | 1.00 | (0.27-3.71) | 1.00 | 87.7 | 0.00 | 2.05 | (0.92-4.55) | 0.08 |
1 | 101 | 87 | 74.2 | |||||||||
Inflammatory disease | No | 153 | 90.2 | 0.09 | 81.9 | 0.10 | 2.50 | (0.96-6.52) | 0.06 | |||
Yes | 19 | 84.7 | 58.5 | |||||||||
Grade | 1 or 2 | 99 | 89.8 | 0.82 | 80.8 | 0.39 | ||||||
3 | 73 | 91.1 | 78.3 | |||||||||
Estrogen receptor | Negative | 64 | 80 | 0.05 | 5.52 | (1.84-16.55) | 0.00 | 72.2 | 0.14 | 2.50 | (1.22-5.12) | 0.01 |
Positive | 101 | 95.1 | 84.9 | |||||||||
Chemotherapy regimen | Anthracyc | 97 | 90.7 | 0.22 | 76.9 | 0.26 | ||||||
Anthracyc | 54 | 85.9 | 86.5 | |||||||||
Surgery | BCS | 90 | 95.8 | 0.04 | 3.26 | (0.97-10.94) | 0.06 | 81.9 | 0.76 | |||
MRM | 82 | 82.8 | 75.8 | |||||||||
Combined yp stage | 0 - II | 163 | 89.9 | 0.97 | 81 | 0.09 | ||||||
III | 9 | 87.5 | 55.6 | |||||||||
pCR | No | 143 | 88.4 | 0.18 | 77.2 | 0.13 | ||||||
Yes | 28 | 95.7 | 91.7 | |||||||||
ypN stage | 0 | 95 | 89.3 | 0.94 | 1.30 | (0.42-3.95) | 0.65 | 88.9 | 0.00 | 3.17 | (1.33-7.15) | 0.01 |
1 | 77 | 90.1 | 69 | |||||||||
>1 node involved | No | 138 | 90.5 | 0.33 | 82.3 | 0.06 | 1.26 | (0.58-2.75) | 0.56 | |||
Yes | 34 | 86.5 | 69.3 | |||||||||
Trastuzumab use | No | 146 | 91.7 | 0.09 | 0.06 | 77.1 | 0.03 | 0.21 | (0.03-1.53) | 0.12 | ||
Yes | 26 | 79.3 | 93.3 | |||||||||